Windlas Biotech Limited is established in 2001 by Ashok Kumar Windlass, Hitesh Windlass, Manoj Kumar Windlass, and AKW WBL Family Pvt Trust are the company promoters.
Windlas Biotech IPO It is one of India’s major pharmaceutical formulations contract development and manufacturing organizations (CDMO). The firm provides CDMO services ranging from product discovery to product development, licensing, and commercial manufacture of generic products, including complex generics.
Windlas Biotech’s major customers include Pfizer Ltd, Sanofi India Ltd, Cadila Healthcare Ltd, Emcure Pharmaceuticals Ltd, Eris Lifesciences Ltd, Intas Pharmaceuticals Ltd, and Systopic Laboratories Private Limited.
Check :- Upcoming IPO 2021
Its production facilities are in Dehradun and have an installed capacity of 7,063.83 million tablets/capsules, 54.46 million pouches/sachets, and 61.08 million liquid bottles.
| Windlas Biotech IPO details | |
| Subscription Dates | 4-6 Aug 2021 |
| Price Band | 448 – 460 Rs Per Share |
| Offer For Sale | 236.54 crore |
| Fresh issue | 165 crore |
| Total IPO size | 401.54 crore |
| Minimum bid (lot size) | 30 Rs Share |
| Face Value | 5 Rs share |
| Retail Allocation | 35% |
| Listing On | NSE, BSE |
| Windlas Biotech Limited Market Lot | |||
| Lot | No of Shares | Amount | |
| Minimum | 1 | 30 Shares | 13,800 Rs |
| Maximum | 14 | 420 Shares | 193,200 Rs |
Financial Record of the last year (In Million)
Financial Period : 31-Dec-20
Total Assets : 3,158.83
Total Revenue : 3,230.94
Profit After Tax : 96.74
Earnings Per Share (EPS) FY2021 : 8.70
Registrar of Windlas Biotech Limited IPO
Link Intime India Private Limited
C-101, 1st Floor, 247 Park
Lal Bahadur Shastri Marg,
Vikhroli (West) Mumbai – 400 083
Phone: +91 22 4918 6200
Fax: +91 22 4918 6195
Website: http://www.linkintime.co.in
Windlas Biotech Limited Contact Details
Windlas Biotech Limited
40/1, Mohabewala Industrial Area,
Dehradun, 248110
Phone: +91 135 6608000
Website: http://www.windlasbiotech.com/
Windlas Biotech IPO Lead Managers
SBI Capital Markets
DAM Capital Advisors
IIFL Securities Ltd